FDA Approves XTANDI — Astellas Pharma US, Inc.

Astellas Pharma Inc. received FDA approval for its oral androgen receptor antagonist Enzalutamide, assigned the brand name XTANDI, to treat certain metastatic prostate cancer patients at high risk of progression. The approval immediately bolstered Astellas' leadership in the prostate cancer market by providing a critical alternative to existing androgen deprivation therapies.